Eli Lilly Raises 2026 Revenue Outlook to $91B-$92B as Q3 Mounjaro Sales Rise 65%

5.4 · 1d ago · US · FINANCE

The Facts

  • Eli Lilly raised its full-year sales forecast on continued demand for its obesity and diabetes drugs. ✓2 · CNBC, Bloomberg
  • Eli Lilly raised its 2026 revenue guidance to $91 billion-$92 billion, from a previous $85 billion-$87 billion. CNBC only
  • Mounjaro worldwide Q3 revenue rose 65% to $10.72 billion (about $5 billion in the U.S.), versus analyst expectations of $10.10 billion worldwide and $4.79 billion U.S. (StreetAccount). CNBC only
  • Zepbound Q3 revenue was $5.35 billion, up 49% year over year, versus the $5.09 billion analysts expected (StreetAccount). CNBC only
  • Foundayo, Lilly's oral GLP-1 obesity pill approved in the U.S. in April, took in $184 million in Q3, below the roughly $229 million analysts expected (StreetAccount). CNBC only
Dive deeper · 7 more factsShow less
  • Lilly's 2026 adjusted EPS guidance is $35-$36, versus a prior $35.50-$36.50. The company said underlying profit guidance rose $4.07 per share at the midpoint, offset by $4.57 per share in deal-related charges. CNBC only
  • Q3 net income was $6.45 billion ($7.22 per share), versus $5.58 billion ($6.21 per share) a year earlier; adjusted EPS was $7.48. CNBC only
  • U.S. revenue rose 34% to $15.1 billion on 41% higher volume, partly offset by a 7% drop in realized prices. Ex-U.S. revenue rose 47% to $9.3 billion on 76% higher volume and 29% lower prices. CNBC only
  • Lilly held 63% of the U.S. obesity and diabetes drug market in Q3 versus Novo Nordisk's 36.6%, and 58.4% internationally versus Novo's 41.6%, per Lilly's earnings presentation. CNBC only
  • The quarter included a $410 million sales-based milestone payment for Jardiance tied to the Boehringer Ingelheim collaboration. CNBC only
  • Lilly shares rose about 4% in premarket trading. CNBC only
  • Lilly agreed to buy Merida Biosciences to develop treatments for autoimmune and allergic diseases. CNBC only

Context

Eli Lilly reported third-quarter results that exceeded analyst estimates and raised its full-year revenue outlook, driven by Mounjaro and Zepbound. Higher volumes more than offset lower realized U.S. prices, which followed a drug pricing agreement with the Trump administration last year.

Sales of the new obesity pill Foundayo fell short of expectations. Lilly's guidance for adjusted earnings per share was narrowed lower at the top end due to charges tied to deals in the quarter.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 3.

7 Business Analyst Eli Lilly, a mega-cap pharma bellwether, raised its 2026 revenue guidance by roughly $5 billion with Mounjaro and Zepbound sales beating estimates, a market-moving earnings event that drove a roughly 4% premarket rally, though it is a single company's quarterly report rather than a sector-wide or policy shock.
6 News Editor A major pharmaceutical company's quarterly earnings beat and raised revenue guidance is a concrete, market-moving financial event affecting investors and the obesity drug market, but it is corporate earnings news of moderate broad public importance rather than widespread immediate impact on the general population.
6 Critical Reader Eli Lilly's raised revenue guidance and beat on Mounjaro and Zepbound are concrete, measurable financial results for a major drugmaker, but the story concerns one company's earnings rather than broad societal impact.
5 Policy Expert This is a corporate earnings report and guidance raise for a major drugmaker, with a notable acquisition, but it reflects company financial performance rather than enacted laws, rulings, or broad immediate public impact, placing it in the moderate newsworthy range.
5 Informed Citizen A large drugmaker's earnings beat and guidance raise is newsworthy for investors and the obesity drug market, but it has limited direct impact on ordinary people within a week.
5 Science & Tech Analyst This is a major pharma earnings report with a substantial guidance raise and notable market share data, but it is a corporate financial update of significant interest to investors rather than broad immediate public impact or a peer-reviewed or consequential technology shift.
4 Global Affairs Analyst This is a corporate earnings report with a raised revenue forecast for a major drugmaker, which is significant for markets and the obesity-drug sector but has limited geopolitical or broad public impact.

Sources (2)

← All stories